First Patient Dosed in CUPID Study of Telix’s Targeted Alpha Therapy Candidate for Prostate Cancer
Telix announces the first patient has been dosed in its ‘CUPID’ Phase I study of TLX592 in patients with advanced prostate cancer.
ZIRCON Phase 3 Renal Cancer Imaging Study: Progress Update
Progress update on the ZIRCON Phase 3 study for the imaging of renal cancer with Positron Emission Tomography (PET).
First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer
Telix announces that a first patient has been dosed in a Phase I study of TLX250-CDx in patients with bladder cancer.
IPAX-1 (TLX101 for Glioblastoma Therapy) Clinical Trial Update
Telix announces preliminary safety data from the IPAX-1 Ph I/II study, with a follow-on study being planned in front-line therapy.
TLX66 Meets Study Objectives in Patients with AL Amyloidosis
Telix announces bone marrow conditioning investigational candidate TLX66 has met study objectives, demonstrating the initial safety profile in patients with AL amyloidosis.
First Patient Dosed in Japanese Prostate Cancer Imaging Study
Telix announces the first patient has been dosed in a clinical study in Japan using Telix’s investigational prostate cancer imaging product, Illuccix®.
Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy
Telix has been granted HREC approval and received CTN clearance by the TGA to commence a Phase III study of the Company’s prostate cancer therapy candidate TLX591, in patients with advanced prostate cancer.
Japanese Renal Cancer Imaging Trial Meets Study Objectives
Telix announces the Company’s ZIRDAC-JP study of its renal cancer imaging product demonstrates safety and tolerability in Japanese patients.
Launch of the International NOBLE Registry of Telix’s SPECT-Based Prostate Cancer Imaging Agent
Telix announces the launch of the international NOBLE Registry of Telix’s ‘rest of world’ prostate cancer imaging agent and the dosing of the first patient
Telix and Kanazawa University Cleared to Commence Prostate Cancer Imaging Study in Japan
Telix Japan receives Clinical Trial Notification (CTN) clearance to commence a Phase I trial of its prostate cancer imaging product in Japan.